Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“The New PhRMA:” Education, Communication Are Cornerstones, Tauzin Says

Executive Summary

The Pharmaceutical Research & Manufacturers of America will become a resource to support communications efforts by member companies as part of an expanded mission, PhRMA CEO Billy Tauzin told the trade association March 18 in Washington, D.C

You may also be interested in...



PhRMA guidelines for DTC on deck

Pharmaceutical Research and Manufacturers of America is expected to release its revised guidelines for direct-to-consumer ads in early 2009, Hugh O'Neill, Sanofi-Aventis' head of market access and business development, reported at a conference on DTC Oct. 29. He indicated the code will include some type of moratorium on ads (1"The Pink Sheet," July 21, 2008, p. 27). Good news for PhRMA: Billy Tauzin, the trade group's president, "expects to be back on the job in the very near future," according to Senior VP Ken Johnson. Tauzin is on medical leave, but the association is "in daily contact with Billy as we begin to make plans for next year," Johnson says. "The great news is that he remains cancer-free and expects to remain at the helm of PhRMA for many years to come." Tauzin often uses a personal account of his battle with cancer, and the role of pharmaceuticals in his recovery, as part of his advocacy for the industry (2"The Pink Sheet," March 28, 2005, p. 31)

PhRMA guidelines for DTC on deck

Pharmaceutical Research and Manufacturers of America is expected to release its revised guidelines for direct-to-consumer ads in early 2009, Hugh O'Neill, Sanofi-Aventis' head of market access and business development, reported at a conference on DTC Oct. 29. He indicated the code will include some type of moratorium on ads (1"The Pink Sheet," July 21, 2008, p. 27). Good news for PhRMA: Billy Tauzin, the trade group's president, "expects to be back on the job in the very near future," according to Senior VP Ken Johnson. Tauzin is on medical leave, but the association is "in daily contact with Billy as we begin to make plans for next year," Johnson says. "The great news is that he remains cancer-free and expects to remain at the helm of PhRMA for many years to come." Tauzin often uses a personal account of his battle with cancer, and the role of pharmaceuticals in his recovery, as part of his advocacy for the industry (2"The Pink Sheet," March 28, 2005, p. 31)

DTC Principles Still On PhRMA’s Agenda; J&J Tries Leading By Example

Pharmaceutical companies should acknowledge that direct-to-consumer advertising may "inadvertently" minimize risk information, incoming Pharmaceutical Research & Manufacturers of America Chairman William Weldon (J&J) told the association's annual meeting in Washington, D.C. March 18

Related Content

Topics

UsernamePublicRestriction

Register

PS045586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel